Shares of Viking Therapeutics fell much than 30% successful premarket trading Tuesday aft the institution released mid-stage proceedings data connected its obesity pill that disappointed investors.
The results could beryllium a stroke to Viking, which was once seen arsenic a blistery M&A target arsenic pharmaceutical companies scramble to articulation the booming marketplace for obesity and diabetes drugs. It could reenforce Eli Lilly and Novo Nordisk's dominance successful the space, particularly arsenic they develop pills for value loss that could participate the marketplace years up of the tablet formulation of Viking's drug, VK2735.
Jared Holz, Mizuho wellness attraction equity strategist, said successful an email Tuesday that the information "probably shutters anticipation for [Viking] to beryllium a bigtime subordinate successful the oral obesity marketplace implicit the adjacent to mean term."
The contention to make a much convenient obesity pill has been fraught, arsenic companies specified arsenic Pfizer person had to scrap erstwhile contenders and bring distant caller ones.
Viking's once-daily pill helped patients suffer up to 12.2% of their value astatine astir 3 months. The institution besides said that value nonaccomplishment didn't plateau, which means patients could suffer adjacent much successful a longer-term study.
It's hard to straight comparison the pill's signifier 2 proceedings information to the results of oral drugs further on successful development, including treatments developed by Eli Lilly and Novo Nordisk.
Holz added that the results connected Viking's pill "look inferior" to those of Eli Lilly's oral cause "on astir each metrics." The highest dose of Eli Lilly's regular pill helped patients suffer 12.4% of their assemblage weight, oregon 11.2% careless of discontinuations, astatine 72 weeks successful a signifier 3 trial.
Holz pointed to the precocious complaint of patients who discontinued Viking's cause for immoderate crushed implicit 13 weeks, which was astir 28%. Meanwhile, astir a 4th of radical discontinued Eli Lilly's pill, orforglipron, for immoderate crushed implicit 72 weeks.
That's "a overmuch longer proceedings and truthful [Lilly] looks acold amended head-to-head," Holz said.
Viking said the astir communal reasons for patients to discontinue attraction were gastrointestinal broadside effects, the bulk of which were mild to mean successful severity and observed earlier successful treatment. But astir 58% of patients connected the pill reported experiencing nausea and 26% experienced vomiting, compared to 48% and 10%, respectively, among those who took a placebo.
Those broadside effect rates implicit a shorter proceedings play look to beryllium worse than those seen successful trials connected Eli Lilly's pill and the oral mentation of Novo Nordisk's value nonaccomplishment cause Wegovy.
Viking's attraction works by imitating 2 people produced gut hormones called GLP-1 and GIP.
GLP-1 helps trim nutrient intake and appetite. GIP, which besides suppresses appetite, whitethorn besides amended however the assemblage breaks down sweetener and fat.
Eli Lilly's pill and the oral mentation of Novo Nordisk's Wegovy some people GLP-1, but the second has dietary restrictions.
English (US) ·